Publication | Closed Access

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

24-Month Overall SurvivalFirst-line TherapyOncologyPathologyImmune Checkpoint InhibitorCancer TreatmentMedicineRadiation OncologyLung CancerKeynote-021 Cohort G